Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma

October 8th 2025

VT3989 has received fast track designation from the FDA for unresectable malignant nonpleural or pleural mesothelioma after progression on prior therapy.

Targeted Therapies Move the Needle in NSCLC

October 8th 2025

Benjamin P. Levy, MD, FASCO, discusses how new targeted approaches are affecting the NSCLC treatment landscape.

Dr Gerds on the Differences Between Available JAK Inhibitors for Myelofibrosis

October 8th 2025

Aaron T. Gerds, MD, MS, discusses the FDA-approved JAK inhibitors for myelofibrosis, as well as where the future of myelofibrosis management may lead.

Personalization Drives Next Wave of Metastatic Castration-Sensitive Prostate Cancer Treatment

October 7th 2025

A panel of experts discusses the effort to personalize treatment approaches in metastatic castration-sensitive prostate cancer.

Dr Mouhieddine on a Study of Correlates of Response to Bispecific Antibodies in Myeloma

October 7th 2025

Tarek Mouhieddine, MD, discusses the background and design of a study of correlates of response to bispecific antibodies in relapsed/refractory myeloma.

CDK4/6 Inhibition With Palbociclib Displays Activity in Low-Grade Serous Ovarian Cancer

October 7th 2025

CDK4/6 inhibition with palbociclib demonstrated encouraging efficacy in patients with low-grade serous ovarian cancer.

Dr Gerds on the Importance of Disease-Modifying Therapies in Myelofibrosis

October 7th 2025

Aaron T. Gerds, MD, MS, discusses the limitations of JAK inhibitors and the objectives that the development of next-generation treatments aim to achieve.

AI Integration and Systemic Reform Are Needed to Balance Resource Protection With Timely Access to Treatment

October 7th 2025

Emerging technologies and process reconsiderations may alleviate time and resource stressors oncology teams face when appealing patient insurance denials.

Dr Yee on Daratumumab/Lenalidomide With Ixazomib/Dexamethasone in Multiple Myeloma

October 6th 2025

Andrew Yee, MD, discusses lenalidomide plus ixazomib, dexamethasone, and daratumumab in newly diagnosed multiple myeloma.

Dr Runcie on the Mechanism of Action of XmAb30819 in ccRCC

October 6th 2025

Karie Runcie, MD, discusses the mechanism of action of XmAb30819 in clear cell RCC.

First-Line Dato-DXd Shows OS, PFS Benefits in Immunotherapy-Ineligible TNBC

October 6th 2025

Dato-DXd displayed topline survival benefits in patients with recurrent/metastatic TNBC who could not receive immunotherapy.

FDA Grants Priority Review to Orca-T for Hematologic Malignancies

October 6th 2025

The FDA granted priority review to a biologics license applications seeking the approval of Orca-T for select hematologic malignancies.

Atebimetinib Plus Chemo Makes Case As Potential Frontline Option in Pancreatic Cancer

October 6th 2025

Martin F. Dietrich, MD, PhD, discusses the potential role of atebimetinib plus chemotherapy in frontline pancreatic cancer.

Dr Yuan on Intracranial Activity With T-DXd Plus Pertuzumab in HER2+ Metastatic Breast Cancer

October 3rd 2025

Yuan Yuan, MD, PhD, reports the intracranial efficacy of T-DXd plus pertuzumab in HER2-positive breast cancer, per results from the DESTINY-Breast12 study.

Dr Martini on the Mechanism of Action of Cretostimogene Grenadenorepvec in Urothelial Carcinoma

October 3rd 2025

Alberto Martini, MD, discusses cretostimogene grenadenorepvec in urothelial carcinoma.

Dr LeVee on T-DXd in HER2+ Breast Cancer With/Without Brain Metastases

October 3rd 2025

Alexis LeVee, MD, discusses T-DXd in HER2+ breast cancer with or without brain metastases.

GPC3 Offers Highly Specific Target in HCC

October 3rd 2025

GPC3 has the potential to be targeted in patients with HCC with reduced off-target toxicities compared with other targeted agents.

Dr Sweis on Targeting ENPP3 in Clear Cell Renal Cell Carcinoma

October 2nd 2025

Randy F. Sweis, MD, discusses the potential utility of ENPP3 as a therapeutic target in RCC.

Pembrolizumab Plus Chemotherapy Shows Preliminary Activity in Advanced Penile Cancer

October 2nd 2025

The addition of the PD-1 inhibitor to platinum-based chemotherapy demonstrated proof of concept for the use of chemoimmunotherapy in patients with PSCC.

AMXT 1501 Plus Difluoromethylornithine Nets FDA Orphan Drug Designation in Neuroblastoma

October 2nd 2025

AMXT 1501 plus difluoromethylornithine has received orphan drug designation from the FDA in patients with neuroblastoma.